Acadian Asset Management’s Coherus Oncology CHRS Stock Holding History

Acadian Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$207K	Buy	149,227 +31,361	+27%	+$51.2K	﹤0.01%	1626
2026 Q1	$198K	Buy	117,866 +66,226	+128%	+$118K	﹤0.01%	1592
2025 Q4	$72K	Hold	51,640	–	–	﹤0.01%	1746
2025 Q3	$84K	Hold	51,640	–	–	﹤0.01%	1555
2025 Q2	$37K	Sell	51,640 -145,287	-74%	-$125K	﹤0.01%	1517
2025 Q1	$158K	Buy	196,927 +196,556	+52,980%	+$226K	﹤0.01%	1291
2024 Q4	$0	Sell	371 -56,074	-99%	-$62.9K	﹤0.01%	1702
2024 Q3	$58K	Buy	+56,445	New	+$77.4K	﹤0.01%	1754
2024 Q1	–	Sell	-592,232	Closed	-$1.97M	–	1592
2023 Q4	$1.97M	Buy	+592,232	New	+$1.59M	0.01%	674
2022 Q3	–	Sell	-5,720	Closed	-$41K	–	1682
2022 Q2	$41K	Buy	+5,720	New	+$49.7K	﹤0.01%	1527
2020 Q3	–	Sell	-87,391	Closed	-$1.56M	–	2191
2020 Q2	$1.56M	Sell	87,391 -107,066	-55%	-$1.81M	0.01%	808
2020 Q1	$3.15M	Buy	+194,457	New	+$3.59M	0.02%	481

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Acadian Asset Management's CHRS Position: Q2 2026 in Review

Acadian Asset Management increased its Coherus Oncology (CHRS) stake by 27% in Q2 2026, buying an estimated $51.2K and bringing the position to 149,227 shares worth $207K. The position accounts for ﹤0.01% of the portfolio, ranked #1626.

Acadian Asset Management first reported a position in CHRS in Q1 2020 and has held it in 12 quarters since. The position peaked at $3.15M in Q1 2020. 107 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

Acadian Asset Management held 149,227 shares of Coherus Oncology worth $207K as of Q2 2026.
Acadian Asset Management bought 31,361 Coherus Oncology shares in Q2 2026, an estimated $51.2K.
Coherus Oncology made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1626 holding.
Acadian Asset Management first reported a position in Coherus Oncology in Q1 2020 and has held it in 12 quarters since.
Acadian Asset Management's Coherus Oncology position peaked at $3.15M in Q1 2020.
107 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.